As menmtioned earlier on another thread ACR has a strong buy recommendation from three brokers.(commsec site). I dont know any more as to current valuation or targets. Bioshares has this one in thier Top Five bios. But some of these late stage bios have been a rediculous discounts to real value since the crash. This one has plenty of cash also. The announcement earlier this week states their competitors for male testosterone have problems with their gels rubbung off patients onto children. So maybe ACR gets a dream run thru on the inside because their product doesnt have the same problems. Male hormone therapy is a rapidly growing health care segment.
And who wouldnt want a spray of this stuff after the morning shower.
Add to My Watchlist
What is My Watchlist?
